Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
combined public/private collaborations between academia and industry to determine the
relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker
characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the
study is to continue to discover, optimize, standardize, and validate clinical trial measures
and biomarkers used in AD research.
The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive,
imaging, genetic and biochemical biomarker characteristics of the entire spectrum of
Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild
symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously
funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private
collaboration between academia and industry to study biomarkers of AD. ADNI will continue to
inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome
measures that can be used in clinical trials, and help develop the most effective clinical
This is multi-center, a non-randomized, natural history, non-treatment study. 1,070-2,000
total participants will be enrolled across three cohorts: cognitively normal* (CN), mild
cognitive impairment (MCI) and mild Alzheimer's Disease (AD) dementia. Participants between
the ages of 55-90 (inclusive) will be enrolled at 59 sites in the United States and Canada.
Approximately, 700 - 800 will be rollover participants from previous ADNI studies, and 370 -
1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic
characteristics will be assessed across the three cohorts.
Participants will undergo longitudinal clinical and cognitive assessments, computerized
cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans
and cerebral spinal fluid (CSF) collection for up to 5 years.
*currently recruiting non-Caucasian participants only for the cognitively normal cohort.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.